二氢杨梅素下调大鼠缺血性脑卒中脑组织炎症小体Nod样受体蛋白3的表达

丁慧如; 邓心未; 刘怀存; 程全成; 方璇; 张国梁; 陈春花; 张卫光

doi:10.16098/j.issn.0529-1356.2022.02.001

PDF(7112 KB)

解剖学报 ›› 2022, Vol. 53 ›› Issue (2) : 137-143. DOI: 10.16098/j.issn.0529-1356.2022.02.001

神经生物学

二氢杨梅素下调大鼠缺血性脑卒中脑组织炎症小体Nod样受体蛋白3的表达

丁慧如¹邓心未¹刘怀存¹程全成¹ 方璇¹ 张国梁² 陈春花¹ 张卫光^1*

作者信息 +

Dihydromyricetin down-regulating the expression of nod-like receptor protein-3 in the brain tissue of ischemic stroke in rats

DING Hui-ru¹ DENG Xin-wei¹ LIU Huai-cun¹ CHENG Quan-cheng¹ FANG Xuan¹ ZHANG Guo-liang² CHEN Chun-hua¹ ZHANG Wei-guang^1*

Author information +

文章历史 +

摘要

目的研究二氢杨梅素（DHM）在大鼠缺血性脑卒中治疗方面的作用，并探讨其对炎症小体Nod样受体蛋白3（NLRP3）表达的影响。方法取70只SD大鼠，利用线栓法构建大鼠大脑中动脉栓塞（MCAO）模型，采用Longa评分、TTC染色、Nissl染色、免疫组织化学染色及Western blotting等方法，探讨DHM对MCAO大鼠缺血/再灌注损伤的治疗效果及机制。结果 DHM治疗后MCAO大鼠自主运动能力明显改善，脑组织梗死体积明显减小，脑组织结构和神经元形态较为改善，且DHM治疗后的NLRP3和炎症因子白细胞介素1β（IL-1β）蛋白表达显著降低。结论 DHM能下调炎症小体的表达，进而降低MCAO脑卒中大鼠的脑梗死体积并改善神经行为学表现。

Abstract

Objective To investigate the role of dihydromyricetin (DHM) in the treatment of ischemic stroke in rats, and to explore the effect of DHM on the expression of inflammasome. Methods The middle cerebral artery occlusion (MCAO) model was induced by endovascular suture method. The therapeutic effect and mechanism of DHM were investigated by Longa score, TTC staining, Nissl staining, immunohistochemical staining and Western bloting. Results After DHM treatment, the motor capacity of MCAO rats was significantly improved, the infarct volume was significantly reduced, the brain structure and neuron morphology were improved, and the expressions of nod-like receptor protein-3 (NLRP3) and interleukin-1β(IL-1β) decreased significantly. Conclusion DHM can down-regulate the expression of NLRP3 and thus reduces the cerebral infarction volume and improves neurobehavioral performance in MCAO rats.

导出引用

丁慧如邓心未刘怀存程全成方璇张国梁陈春花张卫光. 二氢杨梅素下调大鼠缺血性脑卒中脑组织炎症小体Nod样受体蛋白3的表达[J]. 解剖学报. 2022, 53(2): 137-143 https://doi.org/10.16098/j.issn.0529-1356.2022.02.001

DING Hui-ru DENG Xin-wei LIU Huai-cun CHENG Quan-cheng FANG Xuan ZHANG Guo-liang CHEN Chun-hua ZHANG Wei-guang. Dihydromyricetin down-regulating the expression of nod-like receptor protein-3 in the brain tissue of ischemic stroke in rats[J]. Acta Anatomica Sinica. 2022, 53(2): 137-143 https://doi.org/10.16098/j.issn.0529-1356.2022.02.001

中图分类号： R743

参考文献

［1］ Seners P, Turc G, Oppenheim C, et al. Incidence, causes and predictors of neurological deterioration occurring within 24 hours following acute ischaemic stroke: a systematic review with pathophysiological implications［J］. J Neurol Neurosurg Psychiatry, 2015, 86(1):87-94.

［2］ Liu X, Zhang Z, Ruan J, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores［J］. Nature,2016, 535(7610):153-158.

［3］ Sun P, Yin JB, Liu LH, et al. Protective role of dihydromyricetin in Alzheimer’s disease rat model associated with activating AMPK/SIRT1 signaling pathway［J］. Biosci Rep, 2019, 39(1): BSR20180902.

［4］ Semcheddine F, Guissi NEI, Liu XY, et al. Effects of the preparation method on the formation of true nimodipine SBE-β-CD/HP-β-CD inclusion complexes and their dissolution rates enhancement［J］. AAPS Pharm Sci Tech, 2015, 16(3):704-715.

［5］ Wang J, Jiang C, Li X, et al. The protective mechanism of progesterone on blood-brain barrier in cerebral ischemia in rats［J］. Brain Res Bull, 2009, 79(6):426-430.

［6］ Poh L, Kang SW, Baik SH, et al. Evidence that NLRC4 inflammasome mediates apoptotic and pyroptotic microglial death following ischemic stroke［J］. Brain Behav Immun, 2019, 75:34-47.

［7］ Walsh JG, Muruve DA, Power C. Inflammasomes in the CNS［J］. Nat Rev Neurosci, 2014, 15(2):84-97.

［8］ Fann DYW, Lee SY, Manzanero S, et al. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke［J］. Cell Death Dis,2013, 4(9):e790.

［9］ Diaz-Ca?estro C, Reiner MF, Bonetti NR, et al. AP-1 (activated protein-1) transcription factor Jun D regulates ischemia/reperfusion brain damage via IL-1β (interleukin-1β) ［J］. Stroke, 2019, 50(2):469-477.

［10］ Shen Y, Lindemeyer AK, Gonzalez C, et al. Dihydromyricetin as a novel anti-alcohol intoxication medication［J］. J Neurosci, 2012, 32(1):390-401.

［11］ Hu Q, Zhang T, Yi L, et al. Dihydromyricetin inhibits NLRP3 inflammasome-dependent pyroptosis by activating the Nrf2 signaling pathway in vascular endothelial cells［J］. Biofactors, 2018, 44(2):123-136.

［12］ Feng J, Wang JX, Du YH, et al. Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice ［J］. CNS Neurosci Ther,2018, 24(12):1207-1218.

［13］ Wang YC, Liu QX, Zheng Q, et al. Dihydromyricetin alleviates sepsis-induced acute lung injury through inhibiting NLRP3 inflammasome-dependent pyroptosis in mice model［J］. Inflammation, 2019, 42(4):1301-1310.

［14］ Wu YJ, Chen ChH. Progress of adjuvant treatment with tissue plasminogen activator beyond time window in ischemic stroke［J］.Acta Anatomica Sinica, 2019, 50(6):850-856. (in Chinese)

吴冶君, 陈春花. 缺血性脑卒中治疗时间窗后辅助溶栓治疗的进展［J］. 解剖学报, 2019, 50(6):850-856.